Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Pharmaceuticals ETF

100.09
+1.231.24%
Post-market: 100.090.00000.00%19:43 EDT
Volume:342.44K
Turnover:34.21M
Market Cap:1.56B
PE:9.32
High:100.35
Open:98.35
Low:98.35
Close:98.86
52wk High:108.66
52wk Low:72.94
Shares:15.60M
Float Shares:15.60M
Volume Ratio:0.75
T/O Rate:2.20%
Dividend:1.43
Dividend Rate:1.43%
EPS(TTM):10.74
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly price target lowered to $1,341 from $1,344 at BofA

TIPRANKS
·
Yesterday

Eli Lilly - Taltz and Zepbound Together Show Greater Reductions in Inflammatory Immune Activity

THOMSON REUTERS
·
Yesterday

Eli Lilly: Improvements were Maintained or Further Improved Through Week 52, with Safety Consistent with Known Profile of Each Respective Medicine

THOMSON REUTERS
·
Yesterday

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Advance Understanding of the Interconnected Immune and Metabolic Biology in Adults with Psoriasis and Obesity

THOMSON REUTERS
·
Yesterday

Wells Fargo Adjusts Price Target on Merck & Co to $165 From $170

MT Newswires Live
·
Yesterday

Top 3 Biotech Stocks To Watch In October 2026

Simply Wall St.
·
Yesterday

What Do Johnson & Johnson (JNJ) Trial Wins Mean For Its Drug Pipeline?

Simply Wall St.
·
Yesterday

Medtronic PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Lilly’s Oral Orforglipron Trial Targets Early Obesity Risks, Raising the Stakes in Weight-Loss Pharma

TIPRANKS
·
Yesterday

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Yesterday

Dow's Nearly 150-Point Fall Led by Losses for Shares of Amgen, Johnson & Johnson

Dow Jones
·
Oct 08

1s Could Offer Unexpected Relief from Back and Knee Pain, but Doctors Urge Caution

Dow Jones
·
Oct 08

Bristol-Myers Squibb (BMY) Receives a Buy from J.P. Morgan

TIPRANKS
·
Oct 08

Merck & Company (MRK) Receives a Buy from BMO Capital

TIPRANKS
·
Oct 08

How to invest in healthcare stocks without picking the next Eli Lilly

Simply Wall St.
·
Oct 08

Bristol Myers’ zenbexus in combination shows efficacy in Phase 3 myeloma trial

TIPRANKS
·
Oct 08

Bristol Myers Squibb Says Zenbexus Combo Cuts Multiple Myeloma Progression Risk 51% in Phase 3 Excaliber-RRMM Trial

Reuters
·
Oct 08

Bristol Myers Squibb Announces Zenbexustm (Iberdomide) in Combination with Daratumumab and Dexamethasone (Zdd) Demonstrates Superior Progression-Free Survival VS. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Excaliber Study Shows Pfs Hazard Ratio of 0.49 vs Standard of Care

THOMSON REUTERS
·
Oct 08

Bristol-Myers Squibb Company - Zenbexus Safety Profile Consistent with Previously Reported Findings

THOMSON REUTERS
·
Oct 08